Literature DB >> 15147424

Cancer after kidney transplantation in the United States.

Bertram L Kasiske1, Jon J Snyder, David T Gilbertson, Changchun Wang.   

Abstract

Previous reports of cancer after kidney transplantation have been limited by small numbers of patients in single-center studies and incomplete ascertainment of cases in large registries. We examined rates of malignancies among first-time recipients of deceased or living donor kidney transplantations in 1995-2001 (n = 35 765) using Medicare billing claims. For most common tumors, e.g. colon, lung, prostate, stomach, esophagus, pancreas, ovary and breast, cancer rates were roughly twofold higher after kidney transplantation compared with the general population. Melanoma, leukemia, hepatobiliary tumors, cervical and vulvovaginal tumors were each approximately fivefold more common. Testicular and bladder cancers were increased approximately threefold, while kidney cancer was approximately 15-fold more common. Kaposi's sarcoma, non-Hodgkin's lymphomas, and nonmelanoma skin cancers were more than 20-fold increased than in the general population. Compared with patients on the waiting list, several tumors were more common after transplantation (p < 0.01): nonmelanoma skin cancers (2.6-fold), melanoma (2.2-fold), Kaposi's sarcoma (9.0-fold), non-Hodgkin's lymphoma (3.3-fold), cancer of the mouth (2.2-fold), and cancer of the kidney (39% higher). The rates for most malignancies are higher after kidney transplantation compared with the general population. Cancer should continue to be a major focus of prevention in kidney transplantation.

Entities:  

Mesh:

Year:  2004        PMID: 15147424     DOI: 10.1111/j.1600-6143.2004.00450.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  227 in total

Review 1.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

2.  Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.

Authors:  Aninda Basu; Pallavi Banerjee; Soumitro Pal
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 3.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

4.  Hodgkin lymphoma among US solid organ transplant recipients.

Authors:  Scott C Quinlan; Ola Landgren; Lindsay M Morton; Eric A Engels
Journal:  Transplantation       Date:  2010-11-15       Impact factor: 4.939

5.  Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms.

Authors:  Wai H Lim; Steven J Chadban
Journal:  J Am Soc Nephrol       Date:  2015-11-12       Impact factor: 10.121

6.  [Primary and secondary prevention of skin cancer in organ transplant recipients].

Authors:  A S Lonsdorf; M R Becker; E Stockfleth; K Schäkel; C Ulrich
Journal:  Hautarzt       Date:  2010-03       Impact factor: 0.751

Review 7.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

8.  Risk factors and incidence of malignant neoplasms after kidney transplantation at a single institution in Japan.

Authors:  Kengo Horie; Tomohiro Tsuchiya; Koji Iinuma; Yuka Maekawa; Keita Nakane; Taku Kato; Kosuke Mizutani; Takuya Koie
Journal:  Clin Exp Nephrol       Date:  2019-08-01       Impact factor: 2.801

9.  Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.

Authors:  Dipak Datta; Alan G Contreras; Aninda Basu; Olivier Dormond; Evelyn Flynn; David M Briscoe; Soumitro Pal
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

10.  The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.

Authors:  K Chamie; P M Ghosh; T M Koppie; V Romero; C Troppmann; R W deVere White
Journal:  Am J Transplant       Date:  2008-10-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.